Following the success of our first three-year cost-neutral Read & Publish Open Access (OA) agreement with MALMAD, we are delighted to announce that we have signed a renewal agreement from 1 January 2023 – 31 December 2025.
Researchers at seven leading institutions in Israel can continue to publish an uncapped number of research articles immediately OA without charge in The Company’s hybrid journals – Development, Journal of Cell Science and Journal of Experimental Biology. They also have unlimited access to the journals and their archives dating back to 1853.
Dr. Sigal Lahav Scher, MALMAD Director, says:
“The Company of Biologists was one of the first publishers MALMAD signed a Read & Publish agreement with. We are now very pleased to renew the agreement, covering the costs for researchers at seven institutions in Israel to publish an unlimited number of Open Access articles in all three of The Company’s hybrid journals, whilst also giving them reading access. Our continued cooperation is an important step in the transition to Open Access.”
Sarah Logan, Regional Sales Manager (Africa, The Middle East, Central and Southeast Asia, China and Japan) at The Company of Biologists, says:
“We were one of the first not-for-profit publishers to launch a cost-neutral Read & Publish OA initiative and our 2020-2023 agreement with MALMAD was one of the first we signed. Since then, the initiative has gone from strength to strength. We now have agreements with ten library consortia and we are delighted to be renewing our agreement with MALMAD for a further three years.”
Claire Moulton, Publisher at The Company of Biologists, says:
“Our Read & Publish initiative has been a great success thanks to the tremendous support we have received from libraries and library consortia around the world. Over 600 institutions in 39 countries are now participating, and this helped us to meet our Transformative Journal targets for OA growth in 2021 and 2022.We have had fantastic feedback from authors who benefitted from immediate and fee-free OA publishing during our first three-year agreement with MALMAD, and we look forward continuing our partnership to further accelerate the transition to OA in the biological and biomedical sciences in Israel.”
